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Abstract 
Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic 
benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell 
malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant 
cells and to mediate antibody-dependent cellular cytotoxicity upon Fc receptor stimulation is 
compromised, but the underlying mechanisms are largely unclear. We report here that NK-cells 
activation-dependently produce the tumor necrosis factor family member ‘B-cell activating factor’ 
(BAFF) in soluble form with no detectable surface expression, also in response to Fc receptor 
triggering by therapeutic CD20-antibodies. BAFF in turn enhanced the metabolic activity of 
primary CLL cells and impaired direct and Rituximab-induced lysis of CLL cells without affecting 
NK reactivity per se. The neutralizing BAFF antibody Belimumab, which is approved for 
treatment of systemic lupus erythematosus, prevented the effects of BAFF on the metabolism of 
CLL cells and restored their susceptibility to direct and Rituximab-induced NK-cell killing in 
allogeneic and autologous experimental systems. Our findings unravel the involvement of BAFF 
in the resistance of CLL cells to NK-cell antitumor immunity and Rituximab treatment and point 
to a benefit of combinatory approaches employing BAFF-neutralizing drugs in B-cell 
malignancies.  
Introduction 
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that play an 
important role in the immunosurveillance of hematological malignancies. Their reactivity is 
governed by the integration of activating and inhibitory signals propagated by a multitude of 
surface receptors that determine the quality and intensity of NK-cell responses 1. Owing to their 
ability to mediate antibody-dependent cellular cytotoxicity (ADCC) upon triggering of the Fcγ 
Receptor IIIa (CD16), they substantially contribute to the therapeutic success of antitumor 
antibodies like Rituximab 2. The latter has become an essential component of most treatment 
strategies for B-cell malignancies 3,4. Over the recent years, several studies reported that the 
ability of NK cells to directly lyse the malignant cells and to mediate ADCC is compromised in 
chronic lymphocytic leukemia (CLL) 5–15. The molecular mechanisms underlying these 
observations, however, remain largely unclear. 
In this study, we demonstrate that the resistance of CLL cells to direct and Rituximab-induced 
NK-cell reactivity is facilitated by the tumor necrosis factor (TNF) family member ‘B-cell 
activating factor’ (BAFF). BAFF and its close homologue ‘A proliferation inducing ligand’ (APRIL) 
are mainly produced by immune cells of the myeloid lineage and bind to the two receptors ‘B-cell 
maturation antigen’ (BCMA) and ‘transmembrane activator and cyclophilin ligand interactor’ 
(TACI), while BAFF additionally binds to BAFF receptor (BAFFR). Both are critical factors for 
proliferation, function and survival of peripheral B cells. While at least partially discrepant 
findings have been reported for APRIL, BAFF plays a prominent pathophysiological role in 
autoimmune diseases (for reviews see Mackay and Schneider as well as Dillon et al.) 16,17. 
Accordingly, a BAFF-neutralizing antibody termed Belimumab (Benlysta) and a BAFF- and 
APRIL-inhibiting soluble TACI-Ig molecule (Atacicept) have been developed, the first being 
approved for treatment of systemic lupus erythematosus and the latter being evaluated in 
advanced phase clinical trials 18,19. Both BAFF and APRIL also contribute to the pathophysiology 
of B-cell malignancies by acting as anti-apoptotic and pro-survival factors 20–25. We demonstrate 
that NK cells produce BAFF, in particular upon activation, and this includes triggering of their Fc 
receptor by immunostimulatory CD20 antibodies used in CLL treatment. We further show that 
NK-cell-derived BAFF enhances the metabolic activity of CLL cells and notably also diminishes 
their susceptibility to direct NK-cell lysis and Rituximab-induced ADCC. 
Finally, we report that the CLL-protective effects of BAFF can be neutralized by treatment with 
Belimumab, which sensitizes the leukemia cells to lysis. Our findings not only identify a 
biological mechanism underling the pronounced resistance of lymphoid malignant cells to direct 
and Rituximab-induced NK-cell antitumor immunity, they also unravel the potential of BAFF-
blocking agents to reinforce NK-cell reactivity for immunotherapy of B-cell malignancies.  
Material and Methods  
Cells 
Peripheral blood mononuclear cells (PBMCs) from CLL patients were obtained at time of 
diagnosis prior to therapy. All patients declared written informed consent in accordance with the 
Helsinki protocol, and the study was performed according to the guidelines of the local ethics 
committee. Polyclonal NK cells (pNKCs) were generated using K562-41BBL-IL15 feeder cells 
obtained from St Jude´s Children´s Research Hospital as previously described 26. Resting NK 
cells and monocytes were purified by MACS isolation (Miltenyi, Bergisch-Gladbach, Germany). 
Purity of cell preparations was confirmed by fluorescence-activated cell sorting (FACS) and 
always above 90%. 293-BAFF transfectants and parental controls were described previously 27. 
 
Antibodies and recombinant BAFF 
Recombinant human BAFF (rhBAFF) was from Immunotools (Friesoythe, Germany). BAFF mAb 
1D6 was from eBioscience (San Diego, CA, USA). The anti-mouse PE-conjugate was from Dako 
(Glostrup, Denmark). Rituximab and Obinutuzumab were from Roche (Basel, Switzerland), 
Ofatumumab and Belimumab were from GlaxoSmithKline (Brentford, UK). All other antibodies 
were from BD Pharmingen (San Diego, CA, USA). 
 
PCR analysis 
RT-PCR was performed as described previously 28. Primers were 5′-CCTCAC 
GGTGGTGTCTTTCT-3′ and 5′-AAAGCTGAGAAGCCATGGAA-3′ for BAFF and 5′-
GAGTCAACGGATTTGGTCGT-3′ and 5′-TTGATTTTGGAGGGATCTCG-3′ for GAPDH. 
 
Flow cytometry 
NK cells were incubated with BAFF mAb or isotype control mAb (10 µg/ml each) followed by the 
secondary phycoerythrin conjugate (1:100). Intracellular staining was performed using the 
Cytofix/Cytoperm from BD Biosciences (San Jose, CA, USA) with phycoerythrin-conjugated 1D6 
mAb or isotype control according to the manufacturer´s instructions. NK cells and CLL cells were 
selected by counterstaining for CD56+/CD3- and CD5+/CD19+, respectively. Analysis was 
performed using a FC500 (Beckmann Coulter, Krefeld, Germany). Specific fluorescence indices 
were calculated by dividing median fluorescence obtained with specific mAb by median 
fluorescence obtained with control. Positivity was defined as specific fluorescence index ≥ 1.5. 
 
FACS-based analysis of CLL cell lysis 
Rituximab-induced lysis of CLL cells by autologous NK cells was determined by FACS as 
previously described 29. In brief, PBMCs of CLL patients were cultivated in the presence or 
absence of 500 ng/ml BAFF, Belimumab or control antibody (10 µg/ml each) for 48 h. Then, 
Rituximab (10 µg/ml) was added where indicated for additional 24 h. Afterwards dying and dead 
CD19+/CD5+ CLL cells were identified by FACS owing to 7-aminoactinomycin D positivity. 
Analysis of equal assay volume was ascertained by adding standard calibration beads. 
Percentage of living cells was calculated from triplicate measurements as follows: 7-
aminoactinomycin D negative cells upon treatment/7-aminoactinomycin D negative cells in 
control x 100. 
 
Enzyme-linked immunosorbent assay 
BAFF levels in supernatants were determined by ELISA according to the manufacturer’s 
instructions using the matched-pair detection set from Adipogen (Liestal, Switzerland). Results 
are shown as means of triplicate measurements with s.e.m. 
 
Metabolic activity 
Primary CLL cells were plated at 2 x 106 per well and metabolic activity was measured after 72 h 
using the Cell Proliferation Reagent WST-1 set from Roche according to the manufacturer’s 
instructions. Results are shown as means of triplicate measurements with s.e.m.  
 
NK-cell activation, degranulation and cytotoxicity 
Upregulation of CD69 and CD107a as markers for NK-cell activation and degranulation, 
respectively, was analyzed by FACS. Direct cytotoxicity and ADCC of NK cells against CLL cells 
were analyzed by 2 h BATDA Europium assays as described previously 30.  
 
Purification of NK-cell-derived BAFF 
Belimumab and Rituximab as control were immobilized on CNBr-activated Sepharose 4B (GE 
Healthcare, Chalfont St Giles, UK) according to the manufacturer's recommendations. 
Concentrated NK-cell supernatant was then recirculated on a serial two-column setup overnight 
at 4 °C followed by elution with sodium citrate pH 2.5. Eluates were neutralized, concentrated 
and washed with phosphate-buffered saline by ultrafiltration. Eluates of the Belimumab column 
underwent a second round of purification under identical conditions. 
 
Peptide mass-fingerprint analysis 
Eluates from Belimumab-coated columns were pretreated with dithiothreitol and iodacetamide 
followed by digestion with Trypsin (Sigma Aldrich, St Louis, MO, USA). After ZipTipC18 
(Millipore, Schwalbach, Germany) purification and desalting, peptides were analyzed by liquid 
chromatography-mass spectrometry/mass spectrometry (UltiMate 3000 RSLCnano UHPLC 
system and LTQ orbitrap XL, Thermo Fisher, Waltham, MA, USA) followed by data processing 
and peptide annotation against the human proteome as comprised in the Swiss-Prot database 
(www.uniprot.org), as described previously.31 Search was restricted by enzymatic tryptic 
specificity. Possible methionine oxidation and carbamidomethyl modifications of cysteines were 
taken into account. The false discovery rate was limited to a high confidence to q < 0.01 (1% 
false discovery rate).  
 
Results 
BAFF is activation-dependently produced by NK cells as soluble, but not as surface-
expressed protein 
A previous study reported that activated NK cells express BAFF at the protein level 32, but 
whether it is expressed on the cell surface or released in soluble form was not studied. After 
characterizing available reagents for BAFF detection (Supplementary Figure 1A), we performed 
FACS analyses with resting NK cells within PBMCs of healthy donors as well as pNKCs. We 
found that NK cells express no or very low levels of surface BAFF (Figure 1a and 
Supplementary Figure 1B). NK cells were also surface-negative for APRIL, which reportedly is 
not produced in a membrane-bound form 33. Notably, mRNA of both BAFF and APRIL was 
detected by RT-PCR in resting and polyclonal NK cells (Figure 1b and data not shown). Next, 
we analyzed culture supernatants from isolated resting NK cells and pNKCs for BAFF and 
APRIL by ELISA. APRIL was never detectable, whereas soluble BAFF was produced by NK 
cells in all cases with higher levels observed with pNKCs (Figure 1c and data not shown). In line, 
BAFF protein was detected by intracellular FACS analysis in NK cells among PBMCs of healthy 
donors, pNKCs and notably also in NK cells of CLL patients, which displayed pronounced BAFF 
levels (Figure 1d). 
To determine whether and how BAFF production by NK cells is regulated, pNKCs were cultured 
alone or in the presence of the cytokines IL-2 and IL-15 which induce a potent general 
activation. To mimic CD16 stimulation, we employed culture of the NK cells on immobilized 
Rituximab, Ofatumumab and Obinutuzumab, the three CD20 antibodies approved for CLL 
treatment. Although induction of BAFF surface expression was never observed, all stimuli 
significantly increased the release of soluble BAFF, which was mirrored by enhanced BAFF 
mRNA levels in NK cells. Ofatumumab and Obinutuzumab, which mediate more pronounced 
immunostimulatory effects as compared with Rituximab 34,35, induced higher BAFF release as 
compared with Rituximab, which in case of Obinutuzumab reached statistical significance. This 
was mirrored by our results regarding the increase of BAFF protein levels detectable by FACS 
intracellularly in NK cells (all P < 0.05, Student’s t-test) (Figures 1e, f and data not shown).  
 
BAFF stimulates metabolic activity and protects CLL cells from direct and Rituximab-
induced NK lysis 
Next, we employed primary CLL cells in WST-1 assays, which revealed a dose-dependent 
induction of leukemia cell metabolic activity upon exposure to rhBAFF (Figure 2a). Then, we 
purified BAFF from NK-cell culture supernatants and analyzed this preparation (nkBAFF) by 
liquid chromatography-mass spectrometry/mass spectrometry. Tryptic peptides in preparations 
of 293-BAFF transfectants as control covered most of the sequence of soluble BAFF, and some 
of these fragments were also identified upon analysis of nkBAFF (Tables 1A and B) 36. It is 
noteworthy that one of these peptides has a distinct sequence in cows, excluding the possibility 
that it could originate from fetal calf serum used in these cultures. WST-1 assays with primary 
CLL cells revealed that the nkBAFF purified using a Belimumab-coated column clearly 
stimulated the metabolic activity of the leukemia cells (Figure 2b). Next, primary CLL cells 
cultured in the presence or absence of BAFF were analyzed for their sensitivity to pNKC lysis. 
BAFF exposure for 24 h significantly (all P < 0.05, Student’s t-test) reduced CLL cell 
susceptibility to NK-cell attack. Notably, this BAFF-mediated protection of CLL cells was 
observed for both natural and Rituximab-induced NK lysis and with both rhBAFF and nkBAFF 
(Figure 2c and d). Finally, to more closely mirror the situation in patients, functional analyses 
were performed with freshly isolated PBMCs of CLL patients. FACS-based determination of CLL 
cell viability after incubation in the presence or absence of BAFF and/or Rituximab confirmed 
that rhBAFF significantly (P < 0.05, Student’s t-test) and sometimes fully protected the malignant 
B cells from Rituximab-induced lysis by the patient’s own NK cells (Figure 2e). This protective 
effect was also observed with nkBAFF (Figure 2f). 
 
BAFF reduces CLL cell susceptibility to lysis without affecting NK-cell reactivity 
Next, we incubated CLL cells with or without BAFF for 24 h followed by washing of the leukemic 
cells to exclude an influence of soluble NK-inhibitory factors potentially induced in CLL cells by 
BAFF exposure. Afterwards, pNKCs were co-cultured with the CLL cells in the absence of 
BAFF, which further excluded direct effects of BAFF on the effector cells. Neither in the 
presence nor absence of Rituximab relevant effects of BAFF pretreatment on NK-cell 
degranulation and activation as revealed by FACS for CD107a and CD69, respectively, were 
observed. Notably, this held true with allogenic NK cells and also in our autologous experimental 
setting employing PBMCs of CLL patients directly obtained ex vivo (Figure 3). In line, BAFF 
exposure of the leukemic cells did not alter the expression of immunoregulatory molecules that 
reportedly influence NK-cell reactivity against CLL cells (for example, classical and non-classical 
HLA class I molecules, NKG2D ligands, etc.) or CD20-expression (data not shown). We further 
observed that BAFF did not affect CLL cell proliferation (at least in our in vitro setting), but 
significantly (all P < 0.05, Student’s t-test) protected the leukemic cells from spontaneous 
apoptosis and sustained their survival. Although no effect on the expression of death receptors 
(TRAILR, TNFR1 and CD95/Fas) was detected, this protective effect of BAFF for CLL cells was 
mirrored by a reduction of cleaved PARP as component of their apoptosis machinery 
(Supplementary Figure 2 and data not shown). These results provide evidence that BAFF 
protects CLL cells from lysis without affecting NK reactivity per se. 
 
BAFF neutralization by Belimumab restores CLL cell susceptibility to direct and 
Rituximab-induced NK lysis 
Finally, we determined whether neutralization of BAFF by Belimumab could serve to 
therapeutically overcome its protective effects on CLL cells. First, primary CLL cells were 
exposed to rhBAFF in the presence or absence of Belimumab or control mAb for 72 h. 
Subsequent WST-1 assays revealed that the presence of Belimumab prevented the BAFF-
mediated increase of CLL cell metabolic activity (Figure 4a). Second, we studied whether 
Belimumab also prevented the BAFF-induced resistance of CLL cells to NK-cell attack. 
Cytotoxicity assays revealed that the addition of Belimumab abrogated the protective effect of 
BAFF for CLL cells and significantly (all P < 0.05, Student’s t-test) restored both direct and 
Rituximab-induced lysis by allogeneic NK cells (Figure 4b). Similar results were obtained in our 
autologous experimental system when NK reactivity was induced by treatment with Rituximab 
for 24 h: FACS-based lysis assays revealed that Belimumab significantly (all P < 0.05, Student’s 
t-test) prevented the BAFF mediated resistance of CLL cells to ADCC (Figure 4c). Overall, these 
results demonstrate that Belimumab treatment may serve to overcome the protective effects of 
BAFF and to reinforce direct and Rituximab-induced NK lysis in CLL. 
 
 
 
Discussion 
Owing to their ability to mediate natural and antibody-induced lysis of target cells, NK cells play 
an important role in antitumor immunity 1,2. Induction of NK-cell ADCC contributes to the 
therapeutic effects of antitumor antibodies. It is meanwhile firmly established that this important 
antibody function largely contributes to the success of Rituximab, which is routinely used for the 
treatment of B-cell malignancies including CLL 3,4. However, multiple reports over the last three 
decades described that in CLL, the ability of NK cells to target the malignant cells is 
compromised. Both, low susceptibility of the leukemic cells to NK attack and impaired reactivity 
of patient NK cells have been reported, and notably, this was observed with regard to direct and 
antibody-induced cytotoxicity 5–15. The reportedly higher expression of NK-inhibitory HLA class I 
as well as lower levels of ligands for activating receptors like CD155 and CD112 in lymphoid as 
compared with myeloid leukemias contribute to the same 10. With regard to CLL in particular, not 
only the down-regulation of activating receptors like NKG2D and NKp30 on patient NK cells, but 
also release of the NKp30 ligand BAG6 in soluble form as well as pronounced expression of NK-
inhibitory molecules like non-classical HLA and various TNF family members by the malignant 
cells play a role 9,13,29,37–39.  
Here, we identified the TNF family member BAFF as a mediator of CLL cell resistance to NK-cell 
attack: exposure of CLL cells to BAFF profoundly reduced direct and Rituximab-induced NK lysis 
as revealed by analyses with primary leukemic cells and allogeneic ‘healthy’ as well as 
autologous patient NK cells. With regard to this CLL-protective effect, our finding that NK cells 
themselves produce BAFF is of particular interest. In general, BAFF is mainly expressed and 
released in soluble form by myeloid cells like monocytes/macrophages, dendritic cells and 
neutrophils. However, cells of the lymphoid lineage like B and T cells have also been reported to 
express BAFF, in particular upon activation 16. Here, we report that NK cells as innate 
components of the lymphoid lineage produce BAFF as a soluble factor dependent on their 
activation state, whereas relevant surface expression was never detected. In most cell types, 
BAFF is expressed on the surface and cleaved by a furin convertase.27 In NK cells, BAFF could 
be processed intracellularly and released without being expressed in a membrane-bound form, 
as reported for neutrophils.40 We also detected BAFF protein intracellularly in NK cells of 
healthy donors and notably also of CLL patients. Both intracellular BAFF levels and release of 
soluble protein were increased upon general NK-cell activation with the cytokines IL-2 and IL-15, 
which is in line with a previous study that reported on BAFF expression by NK cells at the protein 
level by western blot 32. 
Notably, enhanced BAFF production was also detected upon CD16 stimulation with Rituximab, 
and even more pronounced effects were observed with Ofatumumab and Obinutuzumab, the 
novel CD20 antibodies approved for CLL therapy. In particular, Obinutuzumab, which is glycol-
engineered to enhance its affinity to CD16 34,35, mediated significantly stronger BAFF induction 
as compared with Rituximab. 
Liquid chromatography-mass spectrometry/mass spectrometry confirmed that BAFF was 
released by NK cells and was present in the nkBAFF preparations employed in functional 
assays. Alike rhBAFF, nkBAFF mediated profound resistance of CLL cells to direct and 
Rituximab-induced NK lysis in allogeneic and autologous experimental assay systems. Notably, 
the activation and degranulation of allogeneic and autologous NK cells both in the absence and 
presence of Rituximab were not affected by BAFF pretreatment of CLL cells. It is therefore 
unlikely that the reduction of NK lysis was due to decreased immunogenicity of the leukemic 
cells. In line, we did not observe effects of BAFF on the expression of various surface molecules 
that reportedly influence NK reactivity against CLL cells or CD20, the target for the therapeutic 
antibodies employed in CLL treatment. Rather, BAFF protects from NK-cell-induced cell death, 
which is supported by our observation that both rhBAFF and nkBAFF stimulated metabolic 
activity, decreased apoptosis and sustained survival of CLL cells. The latter is in line with 
findings of other investigators, which reported that BAFF protects CLL cells from apoptosis and 
enhances NF-κB activity.22,23 The exact molecular mechanism of how BAFF protects CLL cells 
from NK lysis, however, was not addressed in our study and remains to be elucidated. 
Certainly, NK cells are not the only source of BAFF for CLL cells. Besides components of the 
microenvironment, the malignant cells themselves can express BAFF 20,22,23. Nevertheless, 
nkBAFF may contribute to the reportedly compromised efficacy of NK cells to target CLL cells, 
as NK-cell activation upon encounter of the malignant cells would result in locally enhanced 
BAFF levels. Particularly upon antibody treatment, induction of BAFF release by NK cells and 
the resulting resistance to lysis may be counterproductive for the eradication of the leukemia 
cells and limit therapeutic efficacy in CLL. On the basis of these considerations, our finding that 
Belimumab, which is approved for systemic lupus erythematosus treatment, abrogates the CLL-
protective effects of BAFF is of particular interest. Besides increasing the immunostimulatory 
capacity of an antibody itself, it is rational to enhance its therapeutic efficacy by preventing 
mechanisms that allow for tumor immune evasion. For CLL, our approach to reinforce antitumor 
immunity by BAFF neutralization with Belimumab (but likely also other BAFF-blocking reagents) 
appears very promising. The benefit of BAFF neutralization reported in our study was, like the 
role of BAFF in NK-cell immunosubversion per se, proven by using primary leukemia cells of 
CLL patients with allogenic and autologous human NK cells as effectors. The advantage of this 
experimental model is that it not only precludes artifacts caused by differences of expression 
and/or function of BAFF or other TNF superfamily members, but also Fc receptor 
expression/function and the mechanisms and cell types that mediate ADCC in mice 
and men 30,41–46. 
Taken together, the data presented in this study not only provide the first evidence for the 
involvement of (NK-cell-derived) BAFF in the impaired susceptibility of CLL cells to direct and 
Rituximab-induced NK-cell reactivity, they also suggest that combining Belimumab with 
Rituximab, but likely also with Obinutuzumab, Ofatumumab and other systemic treatment 
modalities will be beneficial for CLL therapy. Supporting evidence for this notion is derived from 
a clinical case, where Belimumab sensitized a patient with autoimmune disease for Rituximab 
treatment 47. Future combinatorial clinical studies based on the findings presented in this report 
will be required to validate in vivo our conclusion that Belimumab enhances NK-cell reactivity 
and ADCC in CLL. 
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Figure legends 
Figure 1. BAFF expression and regulation in NK cells.  
(A) CD56+CD3– NK cells within PBMCs of healthy donors (resting NK cells) and pNKCs were 
analyzed for BAFF surface expression by FACS. Combined results obtained with a total of 10 
donors each depicted as individual specific fluorescence index levels with medians of results ( − 
) are shown. 
(B, C) MACS-isolated NK cells and pNKCs from three representative donors were investigated 
for (b) BAFF mRNA expression and (c) release in soluble form by RT-PCR and ELISA, 
respectively. BAFF-transfected 293 cells as well as IFN-γ-treated monocytes and parental 293 
cells as well as Raji cells served as positive and negative controls, respectively. 
(D) Intracellular BAFF protein expression in CD56+CD3– NK cells within PBMCs of healthy 
donors, pNKCs and NK cells of CLL patients was determined by FACS. Combined results 
obtained with a total of at least 10 donors depicted as individual specific fluorescence index 
levels with medians of results ( − ) are shown. 
(E, F) pNKCs were left untreated (untr.) or incubated for 72 h with IL-2 (200 U/ml), IL-15 (10 
ng/ml) or on Rituximab (R), Ofatumumab (Ofa) or Obinutuzumab (Obi) after immobilization to 
plastic. 
(E) BAFF levels in supernatants were analyzed by ELISA. To account for the substantial 
variation observed with NK cells of different donors, results obtained in two exemplary 
experiments (left) and combined data from analyses with six independent donors depicted as 
relative increase compared with untreated NK cells (set to 1 in each individual data set) with 
s.e.m. (right) are shown.  
(F) Intracellular protein levels were determined by FACS and are shown as specific fluorescence 
index levels obtained with NK cells of three independent donors with s.e.m. of results. 
Statistically significant differences (P < 0.05, Student’s t-test) are indicated by *. 
 
Figure 2. Effects of BAFF on CLL cell metabolic activity and susceptibility to direct and 
Rituximab-induced NK cell lysis.  
(A, B) Metabolic activity of primary CLL cells was measured by WST-1 assays after 72 h of 
incubation with (A) the indicated concentrations of rhBAFF or (B) nkBAFF obtained as described 
in the methods section. Flow through and eluates from a Rituximab affinity column served as 
controls. 
(C, D) Primary CLL cells were incubated with BAFF for 24 h followed by washing and analysis in 
Europium cytotoxicity assays with pNKCs in the presence or absence of Rituximab (10 µg/ml). 
(C) Representative results (left) and combined data obtained with rhBAFF (500 ng/ml) in six 
independent experiments with cells of different patients at an E:T ratio of 20:1 (right). 
(D) Representative results of an experiment with nkBAFF out of three with similar results. 
(E, F) PBMCs of CLL patients with moderate leukemia cell counts (40–80%) were left untreated 
or incubated with BAFF in the presence or absence of Rituximab (10 µg/ml). After 72 h, lysis of 
CD19+CD5+ CLL cells was determined by FACS. Results are depicted as means of triplicate 
measurements with s.e.m. 
(E) Exemplary results (left) and combined data of seven experiments with cells of different 
patients (right) and rhBAFF. 
(F) Exemplary results of one representative experiment with nkBAFF out of three with similar 
results. Statistically significant differences (Po0.05, Student’s t-test) are indicated by *. 
 
Figure 3. NK-cell activation and effector function are not altered upon pretreatment of 
CLL cells with BAFF 
(A) Primary CLL cells of six different patients were incubated with or without rhBAFF (500 ng/ml) 
for 24 h followed by washing and culture with allogeneic pNKCs in the presence or absence of 
Rituximab (10 µg/ml). Expression of CD107a and CD69 on CD56+CD3− NK cells were 
monitored by FACS after 4 and 24 h, respectively. 
(B) PBMCs of five different CLL patients with moderate leukemia cell counts (40–80%) were left 
untreated or incubated with rhBAFF in the presence or absence of Rituximab, followed by 
analysis of CD107a and CD69 expression on autologous CD56+CD3− NK cells by FACS after 4 
and 24 h, respectively. Results of untreated cells were set to 1 in each individual data set, and 
data are shown as relative surface expression with medians and s.e.m. of results. Statistical 
significance was calculated by Student’s t-test; ns, not significantly different. 
 
Figure 4. Effects of BAFF neutralization with Belimumab on metabolic activity as well as 
direct and Rituximab-induced NK-cell lysis of CLL cells. 
(A, B) Primary CLL cells from patients with >80% lymphocyte count were incubated with or 
without rhBAFF (500 ng/ml), Belimumab or an isotype control mAb (10 µg/ml each) as indicated.  
(A) After 72 h, metabolic activity was measured by WST-1 assays. Representative results 
obtained with cells from one patient from a total of at least six with similar results are shown. 
(B) After 24 h, Europium cytotoxicity assays were performed with pNKCs (E:T ratio 20:1) in the 
absence (left panels) or presence (right panels) of Rituximab (10 µg/ml). Combined data of six 
independent experiments with cells of different patients are shown. Results obtained with 
untreated CLL cells were set to 1 in each individual data set. 
(C) CLL cells of patients with moderate leukemia cell counts (40–80%) were cultured for 48 h 
with or without rhBAFF (500 ng/ml), Belimumab (10 µg/ml) or isotype control antibody. Then 
Rituximab (10 µg/ml) was added where indicated for additional 24 h followed by analysis of 
CD19+CD5+ CLL cell lysis by FACS. Results are depicted as means of triplicate measurements 
with s.e.m. Combined data of six experiments with cells of different patients are shown. 
Statistically significant differences (P < 0.05, Student’s t-test) are indicated by *. 
 Table 1A. Tryptic peptides identified by MS/MS in positive control (FDR of >1%).  
Peptide Sequence      Position a  Q-value 
#1  TYAMGHLIQR     205–214  0 
#2  LEEGDELQLAIPR     253–265  0 
#3  AVQGPEETVTQDcLQLIADSETPTIQK  134–160  0 
#4  cIQNMPETLPNNScYSAGIAK   232–252  0 
#5  TYAmGHLIQR     205–214  0.001 
#6  VHVFGDELSLVTLFR    217–231  0 
#7  GSYTFVPWLLSFK     161–173  0.002 
#8  cIQNmPETLPNNScYSAGIAK   232–252  0 
Abbreviations: c, carbamidomethyl-cysteine; FDR, false discovery rate; m, methionine sulfoxide; 
MS/MS, spectrometry/mass spectrometry. 
a Amino acid residue position within the BAFF sequence according to Uniprot.org (accession 
Q9Y275 or TN13B_HUMAN). 
 
Table 1B. Tryptic peptides identified by MS/MS in three replicates of purified and 
concentrated cell culture supernatants of pNKCs (FDR of >1%).  
Replicate   Peptide      Q-value 
#1   LEEGDELQLAIPR     0 
AVQGPEETVTQDcLQLIADSETPTIQK  0 
#2   LEEGDELQLAIPR     0 
#3   LEEGDELQLAIPR     0 
Abbreviations: c, carbamidomethyl-cysteine; FDR, false discovery rate; MS/MS, 
spectrometry/mass spectrometry; pNKCs, polyclonal NK cells. 
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